Welcome to Stayble Therapeutics AB´s IR pages
Stayble Therapeutics is a clinical stage pharmaceutical company developing STA363, an intradiscally injected formulation against chronic discogenic low back pain. STA363 is intended for patients not improving after treatment with analgesics and physiotherapy.
LATEST PRESS RELEASES
Stayble appoints Professor Hans Jörg Meisel as a member of the scientific advisory board
Stayble Therapeutics today announced that the company’s scientific advisory board gains new expertise through the appointment of Professor Hans Jörg Meisel, Berlin, Germany. Prof. Meisel adds furth...
Last day of trading in BTA
Stayble Therapeutics AB (“Stayble” or the “Company”) hereby announces that the last day of trading in Paid Subscription Shares (Sw. BTA) will be on 8 March 2021 and stop day will be on 10 Marc...